CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James R. Kasinger Sells 2,850 Shares

CRISPR Therapeutics AG (NASDAQ:CRSP) General Counsel James R. Kasinger sold 2,850 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now directly owns 77,530 shares of the company’s stock, valued at $3,288,822.60. This represents a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

CRISPR Therapeutics Trading Up 2.6 %

CRSP traded up $1.12 during midday trading on Wednesday, hitting $43.49. 1,399,700 shares of the company traded hands, compared to its average volume of 2,256,949. The business has a 50 day simple moving average of $43.02 and a two-hundred day simple moving average of $45.65. CRISPR Therapeutics AG has a 52-week low of $36.52 and a 52-week high of $76.86. The company has a market capitalization of $3.73 billion, a price-to-earnings ratio of -9.95 and a beta of 1.77.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. Equities research analysts anticipate that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts have recently weighed in on CRSP shares. The Goldman Sachs Group cut their price objective on shares of CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research note on Thursday, February 13th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a research report on Thursday, February 13th. Bank of America reduced their price objective on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Evercore ISI upgraded CRISPR Therapeutics from an “in-line” rating to an “outperform” rating and upped their target price for the stock from $60.00 to $99.00 in a research note on Friday, February 14th. Finally, JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have assigned a buy rating to the company. Based on data from MarketBeat.com, CRISPR Therapeutics presently has a consensus rating of “Hold” and an average price target of $73.11.

Institutional Trading of CRISPR Therapeutics

Institutional investors have recently made changes to their positions in the company. Wood Tarver Financial Group LLC purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth approximately $30,000. Ameriflex Group Inc. acquired a new stake in CRISPR Therapeutics during the 4th quarter worth $36,000. GF Fund Management CO. LTD. purchased a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $71,000. Sunbelt Securities Inc. raised its position in shares of CRISPR Therapeutics by 108.6% in the fourth quarter. Sunbelt Securities Inc. now owns 6,165 shares of the company’s stock valued at $238,000 after buying an additional 3,210 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of CRISPR Therapeutics by 2.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 690,191 shares of the company’s stock worth $27,166,000 after buying an additional 13,865 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.